Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Heparinase III limits rat arterial smooth muscle cell proliferation in vitro and in vivo.

Silver PJ, Moreau JP, Denholm E, Lin YQ, Nguyen L, Bennett C, Recktenwald A, DeBlois D, Baker S, Ranger S.

Eur J Pharmacol. 1998 Jun 12;351(1):79-83.

PMID:
9698208
2.
3.

Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury.

Gotha L, Lim SY, Osherov AB, Wolff R, Qiang B, Erlich I, Nili N, Pillarisetti S, Chang YT, Tran PK, Tryggvason K, Hedin U, Tran-Lundmark K, Advani SL, Gilbert RE, Strauss BH.

Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H337-45. doi: 10.1152/ajpheart.00654.2013. Epub 2014 May 23.

4.
5.
6.

Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2.

Chua CC, Rahimi N, Forsten-Williams K, Nugent MA.

Circ Res. 2004 Feb 20;94(3):316-23. Epub 2003 Dec 18.

7.

Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells.

Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW.

Circ Res. 1998 Aug 10;83(3):305-13.

8.

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA.

J Clin Invest. 1996 Oct 15;98(8):1897-905.

9.

Differential expression of alpha 1 type VIII collagen in injured platelet-derived growth factor-BB--stimulated rat carotid arteries.

Bendeck MP, Regenass S, Tom WD, Giachelli CM, Schwartz SM, Hart C, Reidy MA.

Circ Res. 1996 Sep;79(3):524-31.

10.
11.

Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation.

Benitz WE, Kelley RT, Anderson CM, Lorant DE, Bernfield M.

Am J Respir Cell Mol Biol. 1990 Jan;2(1):13-24.

PMID:
2137707
12.

Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation.

Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MN, Tulis DA, Ren J, Sreejayan N.

Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):85-90. Epub 2005 Oct 20.

14.

Platelet-derived growth factor-BB transactivates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells.

Millette E, Rauch BH, Kenagy RD, Daum G, Clowes AW.

Trends Cardiovasc Med. 2006 Jan;16(1):25-8. Review.

PMID:
16387627
15.
16.

Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation.

Myllärniemi M, Calderon L, Lemström K, Buchdunger E, Häyry P.

FASEB J. 1997 Nov;11(13):1119-26.

PMID:
9367346
17.

Growth factors increase pericellular proteoglycans independently of their mitogenic effects on A10 rat vascular smooth muscle cells.

Emoto N, Onose H, Yamada H, Minami S, Tsushima T, Wakabayashi I.

Int J Biochem Cell Biol. 1998 Jan;30(1):47-54.

PMID:
9597753
19.

TAS-301, an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries.

Muranaka Y, Yamasaki Y, Nozawa Y, Terakawa H, Tanahashi Y, Oda N, Satoh A, Asao T, Miyake H, Matsuura N.

J Pharmacol Exp Ther. 1998 Jun;285(3):1280-6.

20.

Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein.

Farb A, Lee SJ, Min DH, Parandoosh Z, Cook J, McDonald J, Pierce GF, Virmani R.

Circ Res. 1997 Apr;80(4):542-50.

Supplemental Content

Support Center